Trial Profile
Open-label, Multicentre, Phase Ib Dose-escalation Study of MEN1611, a PI3K Inhibitor Combined With Trastuzumab With or Without Fulvestrant, in Subjects With PIK3CA Mutated HER2 Positive Locally Recurrent Unresectable (Advanced) or Metastatic (a/m) Breast Cancer Progressed to Anti-HER2 Based Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs MEN 1611 (Primary) ; Trastuzumab (Primary) ; Fulvestrant
- Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms B-PRECISE-01
- Sponsors Menarini Ricerche
- 23 May 2023 Planned End Date changed from 31 Jul 2022 to 21 Dec 2023.
- 23 May 2023 Planned primary completion date changed from 31 Jul 2022 to 21 Dec 2023.
- 30 Nov 2022 According to a Menarini media release, updated safety and efficacy results will be presented during the upcoming San Antonio Breast Cancer Symposium (SABCS) 2022.